Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
EPAX 6000 TG is a concentrated marine-derived omega-3 fatty acid supplement in triglyceride form, primarily composed of eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA). It is manufactured by Epax Norway AS. In clinical research, particularly studies led by the Medical University of Vienna, it is being investigated for its potential to modulate dopamine-dependent cognitive functions and neuroplasticity in patients with schizophrenia and individuals at high risk for psychosis. The mechanism involves the incorporation of long-chain polyunsaturated fatty acids (PUFAs) into neuronal membranes, influencing membrane fluidity, signal transduction, and neuroinflammation. It also acts as a ligand for various nuclear and membrane-bound receptors that regulate metabolic and inflammatory pathways.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on EPAX 6000 TG.